Home » Stocks » GILD

Gilead Sciences, Inc. (GILD)

Stock Price: $67.50 USD 0.89 (1.34%)
Updated Jun 21, 2021 1:11 PM EDT - Market open
Market Cap 83.54B
Revenue (ttm) 25.56B
Net Income (ttm) 301.00M
Shares Out 1.26B
EPS (ttm) 0.24
PE Ratio 281.25
Forward PE 9.29
Dividend $2.75
Dividend Yield 4.07%
Trading Day June 21
Last Price $67.50
Previous Close $66.61
Change ($) 0.89
Change (%) 1.34%
Day's Open 66.99
Day's Range 66.77 - 67.55
Day's Volume 2,295,796
52-Week Range 55.19 - 75.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company's liver disease programs will be presented at The International Li...

9 hours ago - Business Wire

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

3 days ago - Zacks Investment Research

In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.

3 days ago - Zacks Investment Research

Kite Pharma, a unit of Gilead Sciences Inc (NASDAQ: GILD) and Shoreline Biosciences Inc, has entered into a strategic partnership to develop novel cell therapies across various cancer targets. The colla...

3 days ago - Benzinga

SANTA MONICA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogenei...

4 days ago - Business Wire

Biotech stocks are rallying this month; can the trend continue?

Other stocks mentioned: AMGN, BIIB, CLOV, IBB, INO, MRNA, XBI
4 days ago - Zacks Investment Research

The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25 million from Gilead Sciences Inc (NASDAQ: G...

Other stocks mentioned: JNCE
6 days ago - Benzinga

It is hard to believe, but in just over two weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.

Other stocks mentioned: BIO, CVS, STAA
1 week ago - 24/7 Wall Street

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta® (axicabtagene ciloleucel) – the first and only ...

1 week ago - Business Wire

Gilead Sciences (GILD) closed at $68.77 in the latest trading session, marking a -0.75% move from the prior day.

1 week ago - Zacks Investment Research

According to the High Dividend Yield Screen, a Premium feature of GuruFocus, five stocks that have a dividend yield of at least 4% and at least 10 gurus buying shares as of June are Gilead Sciences Inc....

Other stocks mentioned: CVX, GSK, VZ, VZA, XOM
1 week ago - GuruFocus

Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

1 week ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric indication of Epclu...

1 week ago - Business Wire

Best long term hold: Abbvie or Gilead? #AskHalftime

YouTube video

The "Halftime Report" traders answer viewer questions in #AskHalftime.

Other stocks mentioned: ABBV
1 week ago - CNBC Television

Failure is not an option for this small-cap biotech developing a COVID-19 treatment.

Other stocks mentioned: CYDY
1 week ago - The Motley Fool

Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day.

2 weeks ago - Zacks Investment Research

Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cance...

2 weeks ago - Benzinga

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study e...

2 weeks ago - Business Wire

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have dug up Gilead Sciences, Inc. among others.

2 weeks ago - Forbes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in relapsed or refract...

2 weeks ago - Business Wire

Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible.

Other stocks mentioned: AMGN, FUJIY, GE, NNOX, PHG, SIEGY, SKM
3 weeks ago - The Motley Fool

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.

Other stocks mentioned: APT, IBIO, INO, NVAX, QDEL, SRNE
3 weeks ago - InvestorPlace

Despite strong headwinds, there may be hope for this biotech.

3 weeks ago - The Motley Fool

The S&P 500 Index currently trades with a price-earnings multiple in the high 30s. Therefore, it is hardly surprising that investors looking for value are having a difficult time finding stocks with a r...

Other stocks mentioned: CLX, ORI
1 month ago - GuruFocus

Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world.

1 month ago - The Motley Fool

They pay more than double what you'd earn with the average stock in the S&P 500.

Other stocks mentioned: VZ
1 month ago - The Motley Fool

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kit...

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cowen Annual Virtual Oncology Innov...

1 month ago - Business Wire

Tired of expensive stocks being just of reach? Look abroad for some great buying opportunities.

Other stocks mentioned: RDY, TX
1 month ago - The Motley Fool

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities 2021 Virtual Health...

1 month ago - Business Wire

FATE reports a wider Q1 loss on increased R&D expenses.

Other stocks mentioned: BMY, FATE, JNJ
1 month ago - Zacks Investment Research

The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.

1 month ago - The Motley Fool

U.S. aid shipment of remdesivir arrives in India overnight

YouTube video

The United States sent India 125,000 vials of the anti-viral drug remdesivir Sunday night. Its the fourth assistance flight from the United States to India as a way to help combat the surge in cases.

1 month ago - CNBC Television

With the trading day more than halfway over, the broader markets were sliding into the weekend.

Other stocks mentioned: AMZN, TWTR
1 month ago - 24/7 Wall Street

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.

1 month ago - Zacks Investment Research

Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Sales of $6.42 bill...

1 month ago - Benzinga

With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.

1 month ago - The Motley Fool

Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its sales in the fiscal first quarter came in weaker than Wall Street estimates. Sales for its COVID-19 drug (Veklury), however, beat expectations.

1 month ago - Invezz

Gilead (GILD) delivered earnings and revenue surprises of 0.97% and -5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Gilead earnings, revenue both miss

YouTube video

CNBC's Meg Tirrell reports on Gilead's earnings. CNBC's Mike Santoli weighs in.

1 month ago - CNBC Television

Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs...

1 month ago - Reuters

Shares of Gilead Sciences (NASDAQ:GILD) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 23.81% year over year to $2.08, which missed...

1 month ago - Benzinga

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.71 per share of common...

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2021. “We have made strong progress in this fir...

1 month ago - Business Wire

After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks at cheaper prices.

Other stocks mentioned: VRTX
1 month ago - InvestorPlace

We believe that Gilead Sciences stock (NASDAQNDAQ: GILD) is a good buying opportunity at the present time. GILD stock trades near $65 currently and it is, in fact, down 19% from its pre-Covid high of ...

1 month ago - Forbes

Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate...

Other stocks mentioned: ABBV, FHLC, IYH, JNJ, MRK, PFE, TMO ...
1 month ago - Zacks Investment Research

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

Other stocks mentioned: ABBV, BMY, GSK, JNJ, NVS, MRK
1 month ago - InvestorPlace

Other stocks mentioned: ABBV, AMGN, AZN, BMY, JNJ, MRK
1 month ago - GuruFocus

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licen...

1 month ago - Business Wire

About GILD

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of l... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Jan 22, 1992
CEO
Daniel O'Day
Employees
13,600
Stock Exchange
NASDAQ
Ticker Symbol
GILD
Full Company Profile

Financial Performance

In 2020, GILD's revenue was $24.69 billion, an increase of 9.98% compared to the previous year's $22.45 billion. Earnings were $123.00 million, a decrease of -97.72%.

Financial Statements

Analyst Forecasts

According to 32 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 74.49, which is an increase of 10.36% from the latest price.

Price Target
$74.49
(10.36% upside)
Analyst Consensus: Buy